"10.1371_journal.pone.0076280","plos one","2013-10-10T00:00:00Z","Chiori Yabuki; Hidetoshi Komatsu; Yoshiyuki Tsujihata; Risa Maeda; Ryo Ito; Kae Matsuda-Nagasumi; Kensuke Sakuma; Kazumasa Miyawaki; Naoya Kikuchi; Koji Takeuchi; Yugo Habata; Masaaki Mori","Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan","Conceived and designed the experiments: CY HK YT YH MM. Performed the experiments: CY YT RM RI KMN KS KM NK. Analyzed the data: CY HK YT RI KS KT YH MM. Contributed reagents/materials/analysis tools: CY YT RI NK. Wrote the paper: CY HK YH MM.","All authors are employees of Takeda Pharmaceutical Company Limited. Fasiglifam/TAK-875 used in our study is a product in drug development under phase 3 clinical studies, and there is a filed patent: WO 2008/001931. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","10","Chiori Yabuki","CY",12,TRUE,5,8,8,4,TRUE,TRUE,FALSE,0,NA,FALSE
